Pharmacodynamics binding properties

Hansch and Leo [13] described the impact of Hpophihdty on pharmacodynamic events in detailed chapters on QSAR studies of proteins and enzymes, of antitumor drugs, of central nervous system agents as well as microbial and pesticide QSAR studies. Furthermore, many reviews document the prime importance of log P as descriptors of absorption, distribution, metabolism, excretion and toxicity (ADMET) properties [5-18]. Increased lipophilicity was shown to correlate with poorer aqueous solubility, increased plasma protein binding, increased storage in tissues, and more rapid metabolism and elimination. Lipophilicity is also a highly important descriptor of blood-brain barrier (BBB) permeability [19, 20]. Last, but not least, lipophilicity plays a dominant role in toxicity prediction [21]. 

A paper detailing the properties of the multikinase inhibitor ABT-869 (7) did not indicate whether plasma protein binding data were used in the optimization leading to this highly protein-bound (mouse 98.2%, human 99.0%) compound [45]. A dose which provided a 69% reduction in tumor growth and >50% inhibition of receptor phosphorylation and pharmacodynamic response afforded plasma concentration that remained above the cellular IC50 for receptor phosphorylation in the presence of plasma for 4 of 12 h in the bid dosing cycle. 

Identical chemical and physical properties of enantiomers represent a potential source for enantiomer-enantiomer interactions at both pharmacokinetic and pharmacodynamic levels. Whether by competition for plasma- or tissue-binding sites or for drug-metabolizing enzymes, enantiomers may exhibit changes in pharmacokinetics when administered as a racemate compared to individual stereoisomers. The enantiomers of disopyramide exhibit similar clearance and volumes of distribution when given separately. " However, when administered as the racemate, the 5... 

---